Company Filing History:
Years Active: 2018
Title: Laetitia Bussieres: Innovator in Allergen Immunotherapy
Introduction
Laetitia Bussieres is a prominent inventor based in Versailles, France. She has made significant contributions to the field of immunotherapy, particularly in the development of recombinant allergens for diagnostic and therapeutic purposes. Her innovative work has the potential to improve the lives of individuals suffering from allergies.
Latest Patents
Laetitia Bussieres holds a patent for "Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes." This invention involves a method for producing a recombinant protein (rDer p 2) by cultivating a yeast strain transformed with a rDer p 2 coding sequence. The process includes isolating the rDer p 2 protein from the yeast strain. Additionally, the invention encompasses compositions and kits that utilize the rDer p 2 protein for therapeutic or diagnostic applications.
Career Highlights
Bussieres is associated with Stallergenes, a company known for its focus on allergy immunotherapy. Her work at Stallergenes has allowed her to contribute to advancements in the treatment of allergic conditions. With her expertise, she has been able to bridge the gap between research and practical applications in the field of allergen immunotherapy.
Collaborations
Laetitia Bussieres has collaborated with notable colleagues, including Véronique Bordas and Sabi Airouche. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their shared field of research.
Conclusion
Laetitia Bussieres is a trailblazer in the field of allergen immunotherapy, with her innovative patent and contributions to Stallergenes. Her work exemplifies the impact of scientific research on improving health outcomes for individuals with allergies.